Paxlovid for Treatment of Long Covid (STOP-PASC)
Selective Trial Of Paxlovid for PASC (STOP-PASC): Randomized Double-Blind Placebo-Controlled Pilot Trial of Paxlovid for the Treatment of PASC
Sponsor: Pfizer
A PHASE2 clinical study on Long COVID and Post-acute Sequelae of SARS-CoV-2 Infection, this trial is completed. The trial is conducted by Pfizer and has accumulated 11 data snapshots since 2022. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
11 versions recorded-
Oct 2025 — Present [monthly]
Completed PHASE2
-
Oct 2024 — Oct 2025 [monthly]
Completed PHASE2
-
Sep 2024 — Oct 2024 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Nov 2023 — Jul 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
▶ Show 6 earlier versions
-
Sep 2023 — Nov 2023 [monthly]
Active Not Recruiting PHASE2
-
Aug 2023 — Sep 2023 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jun 2023 — Aug 2023 [monthly]
Recruiting PHASE2
-
Jan 2023 — Jun 2023 [monthly]
Recruiting PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Nov 2022 — Dec 2022 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Pfizer
- Stanford University
For direct contact, visit the study record on ClinicalTrials.gov .